Evidence map›Paper›PMID 30124845›Full record

ArticleThe Journal of antimicrobial chemotherapy2018

Phylogenomics of colistin-susceptible and resistant XDR Acinetobacter baumannii.

Mustapha M Mustapha, Bin Li, Marissa P Pacey, Roberta T Mettus, Christi L McElheny, Christopher W Marshall, Robert K Ernst, Vaughn S Cooper, Yohei Doi

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Molecular Characterization of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. TracingMicroorganisms · 2024
    Article
  5. PmrAB, the two-component system ofJournal of bacteriology · 2024
    Article
  6. Article
  7. Colistin Resistance inAntibiotics (Basel, Switzerland) · 2023
    Review
  8. Comparative genomics and molecular epidemiology of colistin-resistantComputational and structural biotechnology journal · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Colistin and Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021
    Article
  15. Antimicrobial Resistance Profile ofJournal of microbiology and biotechnology · 2021
    Article
  16. Article
  17. Article
  18. Colistin ResistantFrontiers in microbiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mustapha M MustaphaDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Bin LiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Marissa P PaceyDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Roberta T MettusDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Christi L McElhenyDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Christopher W MarshallDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Robert K ErnstDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA.
Vaughn S CooperCenter for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yohei DoiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Funding

Colistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2M
Mechanisms and implications of fosfomycin resistance in Escherichia coliR21AI123747 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2016 to 2017
$417k
NIAID NIH HHS R01 AI104895NIAID NIH HHS R21 AI123747
6 · The paper itself

Abstract

Background: Acinetobacter baumannii is a healthcare-associated pathogen with high rates of carbapenem resistance. Colistin is now routinely used for treatment of infections by this pathogen. However, colistin use has been associated with development of resistance to this agent. Objectives: To elucidate the phylogenomics of colistin-susceptible and -resistant A. baumannii strain pairs from a cohort of hospitalized patients at a tertiary medical centre in the USA. Methods: WGS data from 21 pairs of colistin-susceptible and -resistant, XDR clinical strains were obtained and compared using phylogeny of aligned genome sequences, assessment of pairwise SNP differences and gene content. Results: Fourteen patients had colistin-resistant strains that were highly genetically related to their own original susceptible strain with a median pairwise SNP distance of 5.5 (range 1-40 SNPs), while seven other strain pairs were divergent with ≥84 SNP differences. In addition, several strains from different patients formed distinct clusters on the phylogeny in keeping with closely linked transmission chains. The majority of colistin-resistant strains contained non-synonymous mutations within the pmrAB locus suggesting a central role for pmrAB mutations in colistin resistance. Excellent genotype-phenotype correlation was also observed for carbapenems, aminoglycosides and tetracyclines. Conclusions: The findings suggest that colistin resistance in the clinical setting arises through both in vivo evolution from colistin-susceptible strains and reinfection by unrelated colistin-resistant strains, the latter of which may involve patient-to-patient transmission.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsCohort StudiesColistinDrug Resistance, Multiple, BacterialGenomicsHospitalizationHumansMicrobial Sensitivity TestsMutationPhylogenyPolymorphism, Single NucleotideTertiary Care CentersAnti-Bacterial Agentsbeta-LactamasesCarbapenemsColistin

Identifiers

PMID30124845
PMCPMC6198730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.